Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Status:
Withdrawn
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar
in non-pregnant patients with type II diabetes, works in pregnant women. To do this, we will
study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly
your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the
body; specifically, how effectively exenatide helps your pancreas secrete insulin and how
well it controls blood sugar after a meal). There are only two main drug therapies (insulin
injections and glyburide pills) currently used for gestational diabetes and not all women
achieve good enough blood sugar control without side effects. Therefore, we hope to find out
if exenatide might also be helpful in gestational diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
Georgetown University
Collaborators:
Medstar Health Research Institute Washington Hospital Center